CyPath® Lung
Early-stage lung cancer diagnosis
CommercialMarketed as Laboratory Developed Test (LDT)
Key Facts
Indication
Early-stage lung cancer diagnosis
Phase
Commercial
Status
Marketed as Laboratory Developed Test (LDT)
Company
About bioAffinity Technologies
bioAffinity Technologies is dedicated to improving cancer outcomes through its proprietary porphyrin-based platform technology, which enables analysis of the lung microenvironment. The company's lead product, CyPath® Lung, has demonstrated high sensitivity and specificity in clinical studies for detecting early-stage lung cancer and is commercially available as an LDT. bioAffinity is actively expanding its platform to develop targeted diagnostics and therapeutics for other cancers and lung diseases, positioning itself at the intersection of precision diagnostics and cellular-level cancer treatment.
View full company profile